Ingelheim, Germany- September 2024- Boehringer Ingelheim announced that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function.
However, Based on these results, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food and Drug Administration (FDA) and other Health Authorities worldwide. The FDA granted Breakthrough Therapy Designation in IPF in 2022.
“This is the first IPF phase-III-trial in a decade to meet its primary endpoint9,” said Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim. “Today’s announcement represents the next step in our long history in the research of this disease. IPF has a high unmet need for patients, and we are continuously fostering our research activities to develop more options for one of the most common interstitial lung diseases.”
Also Read: Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments
Nerandomilast is an oral, investigational phosphodiesterase 4B (PDE4B) inhibitor and has not been approved for use, therefore safety and efficacy have not been established. Researchers are investigating it as part of the FIBRONEER™ global program, which includes two Phase III studies — FIBRONEER™-IPF4 for patients with IPF and FIBRONEER™-ILD5 for people living with Progressive Pulmonary Fibrosis (PPF).
